transmitted by the bite of a mosquito in which hundreds of sporozoites are released into the vertebrate host's bloodstream. The parasites eventually migrate to the liver-passing through some cell types such as Kupfer cellsand form parasitophorous vacuoles in hepatocytes. At this stage they can either remain dormant as a hypnozoite form (P. vivax or P. ovale), or initiate development that results in the production of thousands of merozoites. The parasites then induce detachment of the infected hepatocyte, allowing it to migrate to the liver sinusoid where budding of parasite-filled vesicles called merosomes 76 occurs. The new merozoites quickly invade erythrocytes where they replicate, sometimes synchronously, in a cycle that may correspond to the cycle of fever and chills in malaria. In response to a cue that is not well understood, some parasites differentiate into male and female gametocytes, which are the forms taken up by the mosquito and which can live quiescently in the bloodstream for weeks. Once they enter the mosquito via a blood meal they rapidly undergo transition into activated male and female gametes. The motile and short-lived diploid parasite form, the ookinete, migrates out of the blood meal, across the peritrophic matrix to the mid-gut wall where an oocyst is formed. After a meiotic reduction in chromosome number sporozoites are formed within the oocyst. Eventually the oocyst ruptures and the sporozoites migrate to the salivary gland where they await transfer to the vertebrate host.
inexpensively in the laboratory. On the other hand, compounds with similar pharmacophores have been synthesized 7 and it may even be possible to engineer yeast to produce such compounds 8 . Currently the drug of last resort, parasite resistance to artemisinin-based drugs has been observed in the rodent models for malaria 9 , and there are a few potential cases of treatment failure in patients 10 . Although these reports have not yet been confirmed in cultured parasites, it seems likely that full-blown resistance to artemisinins will eventually be observed, emphasizing the need for continued drug discovery research. Primaquine remains the only licensed drug that can provide a radical cure of P. vivax but this drug, in addition to its other liabilities, produces haemolytic anaemia in individuals with glucose-6-phosphate deficiency.
Although drugs currently work well against malaria, a vaccine that targets P. vivax or P. falciparum would probably reduce much of the poverty associated with malaria and greatly assist in complete malaria eradication. Recently, encouraging results have been obtained for a vaccine, named 'RTS,S', from GlaxoSmithKline Biologicals that is targeted for licensing in 2011. The vaccine contains a recombinant malaria protein fused to the surface of a hepatitis B protein and is based on the P. falciparum circumsporozoite protein (CSP), an abundant surface protein associated with the pre-erythrocytic phases of parasite development. In limited clinical trials the vaccine has been shown to reduce the number of severe cases of malaria 11 and delay the time to the first clinical episode. Unfortunately, the same studies also showed that children still developed malaria, raising questions about efficacy and drawing comparisons to recent unsuccessful and costly attempts to develop an HIV vaccine. Despite this, the data show that RTS,S is likely to decrease malaria severity and morbidity-were RTS,S to fail, there are still more than 40 subunit vaccines in development and 16 in clinical trials (http://www.malariavaccine.org or reviewed in ref. 12) .
It has been known for a number of years that if sporozoites-the parasite form found in mosquito salivary glands-are attenuated and given as a vaccine, protection superior to that observed with a natural infection is acquired. This has led to the development of a wholeorganism vaccine 13 . Although this vaccine model may be less practical than single-subunit vaccines owing to the cost, distribution challenges and problems with achieving consistently good manufacturing protocols, it still remains the most effective method for inducing protective immunity and efforts are being made to overcome these obstacles. Although the fact that we still don't have a fully protective and licensed malaria vaccine despite decades of effort may be disheartening, one must keep in mind that the development of drugs and vaccines, which are just now entering large-scale clinical trials, was initiated decades ago in a very different era for malaria research. In this period researchers were limited by their ability to work with malaria parasites in the laboratory, and thus vaccine research efforts were mostly focused on a relatively small number of very abundant proteins that could be easily studied.
Malaria genomes
In 2002 the complete genome sequence of P. falciparum was published 14 , along with a partial sequence of P. yoelii yoelii, a rodent parasite often used in vaccine research 15 . In 2005 partial sequences of several other rodent parasites were published 16 , and in this issue the genome sequences of P. vivax (a human malaria parasite) and P. knowlesi (primarily a monkey parasite) are described 17, 18 . In addition, the human genome sequence as well as several races (PEST, M and S) of Anopheles gambiae, the species of mosquito that transmits P. falciparum malaria, have been determined (http://genome.wustl. edu/ and http://www.tigr.org/) and in some cases published 19 . Genome sequences promised a new paradigm in which drug targets might be plucked from the genome 20 , causing an acceleration of preclinical candidates into the drug and vaccine pipelines. Although it may be too early to determine whether public health will be improved, knowledge of the genome has markedly enhanced the pace of basic research on parasite biology, which may eventually lead to the production of new drugs and vaccines. Here we review how genome sequencing has benefited malaria research and opened new avenues of research that may eventually lead to new cures.
The Plasmodium genomes [14] [15] [16] [17] [18] are estimated to contain 23-27 million bases, 14 chromosomes and ,5,500 genes, including many members of multigene families likely to be associated with immune evasion and antigenic variation. They are also rich in low-complexity regions and most have a high A1T content. However, the genome of P. falciparum is exceptionally (A1T)-rich (79.6%) throughout the genome, whereas only portions of the genome of P. vivax show similar levels of richness (overall A1T content of 67.7%), indicating that the extreme A1T content in itself has probably not too much to do with the disease. Nevertheless, it is possible that genes that are exceptionally (A1T)-rich in both species may be more recombinogenic and more likely to be involved in immune evasion. Indeed, associations between (A1T)-richness and recombination frequency have been observed in many species. There are differences between the species. For example, in P. falciparum many of the multigene families involved in immune evasion are, for the most part, located near the ends of chromosomes and are often transcriptionally silent, suggesting possible mechanisms by which genetic diversity could be generated by non-homologous recombination across chromosomes and epigenetic regulation could be established. In contrast, members of multigene families in P. knowlesi are scattered across the chromosomes and are not strictly subtelomeric 18 . Despite the differences, 77% of the proteins are conserved across the different species.
Although parasite genome sequences are available, many of the genes identified do not have homologues in commonly studied model organisms and often lack a clear cellular function 14 . Even with the recently completed P. vivax study almost one-half of the predicted genes still lack characterized orthologues in other systems. Considering the impact that malaria parasites have had on human health it seems remarkable that we know as little as we do. For example, we do not know the basis for sex determination in malaria parasites or exactly how parasites become committed to sexual development. Little is known about the liver stages and how the parasites home to the liver but then pass through transverse some cells while forming parasitophorous vacuoles in others. The situation is particularly acute in P. vivax, which cannot be cultured. In fact there is debate as to whether the hypnozoite, the dormant parasite liver form involved in relapse in P. vivax malaria, is a distinct stage or merely an early exoerythrocytic form whose development has been arrested. Recently it was shown that parasite metabolism inside a human may differ from parasite metabolism in laboratory culture, again highlighting how little is known about the role of the parasite genes during active patient infections 21 . Although research into such questions may be regarded as peripheral to the central objective of finding better drugs and vaccines, further investigation into basic biology will probably assist translational research in serendipitous ways.
Functional studies of malaria genomes
The goal of functional genomics is to determine what the different genes comprising the genome are likely to do for the organism (in this case the Plasmodium species), often using high-throughput tools such as microarrays or mass spectrometers. Transcriptional and proteomic analyses of the complement of genes within the genome at different life cycle stages can serve as a form of 'virtual genetics' in which regulons of co-transcribed genes can be defined by virtue of their expression pattern across many different conditions. Thus, if a gene shows a large induction during early liver stage development, there is a good chance that this is the time when its protein product will be required 22, 23 . These data can then be used to predict possible functions for parasite genes and to overcome the lack of powerful forward genetic methods that have advanced knowledge in so many other organisms. Comprehensive expression analyses of different parasite life cycle stages have been performed for a number of malaria parasite species 16, 21, [23] [24] [25] . Because these data are only predictions, other high-throughput methods for collecting genome-wide data can assist in determining which of the genes revealed in a gene expression experiment are likely to be involved in a process of interest. Two-hybrid mapping 26 and proteomics 16, 27, 28 produce complementary data. Comprehensive analysis of the parasite proteome from male and female gametocytes has revealed genes contributing to the phenotypic differences between parasites of different sexes 29 . Genome database websites such as PlasmoDB (http://www.plasmodb.org) have served to disseminate the data from such studies and have assisted the research activities of everyone interested in malaria. New genetic tools 30, 31 have been introduced that assist those interested in testing these predictions and may eventually be used in large-scale knockout or mutagenesis projects. Genome-scale protein crystallization projects are also underway, which should also help the pace of drug development 32, 33 . One piece of information that has come from comprehensive proteomic and transcriptional profiling is that translational control probably has an important role in gene regulation during development. Although experiments have generally shown that there is a good correlation between transcript and protein abundance, there are notable discrepancies. In a number of cases genes appear to be transcribed but then not translated until the organism has made the rapid transition between warm-and cold-blooded hosts. Most notably, transcripts needed for gamete formation in the mosquito are produced in gametocytes in the mammalian host, but only translated after the transition-initiated by an increase in xanthurenic acid and a calcium-dependent signalling cascade 34 -has been made 16, 35 . Specific genes involved in translational repression have been characterized 36 . Although translational silencing clearly has a role in gene regulation when the parasite moves from human to mosquito, it seems likely that this is also occurring in the sporozoites, which inhabit the salivary glands of mosquitoes. The sporozoite form must also be prepared for a rapid and unexpected transition to a warmblooded organism. Indeed, the liver-stage-associated protein 2 is not detected until 2 days after the parasite invades the liver 37 , even though its cognate transcript is one of the most abundant in the sporozoite salivary gland transcriptome 24 . Accordingly, it was noted that the malaria parasite genome seems to encode many genes involved in translational regulation, such as helicases and RNA binding proteins, but relatively few transcription factors 14 , and many of these are transcribed in gametocytes and sporozoites. Many non-coding RNAs are transcribed by the parasite genome and some of these may have interesting roles in controlling developmental processes 38 . Expression profiling has also revealed groups of genes with a probable involvement in the parasite's interaction with the mosquito 23 and which could be candidates for transmission-blocking vaccines. Transmission-blocking vaccines (reviewed in ref. 39 ), which would be directed towards proteins associated with the sexual phases of development (gametocytes or gametes), would not protect from the clinical manifestations of malaria but would altruistically prevent an infected individual from passing the disease on to the next person, potentially assisting in eradication. Functional genomic methods and mosquito genome sequence have been used to discover genes involved immunity 40 and in host-parasite interactions. Work has shown that some of these genes are critical for parasite survival or are associated with the mosquito's ability to clear parasites 41 , suggesting new vector-based control strategies 42 . Although there are of course logistical, environmental and ethical issues associated with releasing recombinant mosquitoes that are unable to transmit malaria, the idea remains appealing.
Genome-wide analysis of antigenic variation
Creating catalogues of genes potentially involved in parasite processes or understanding parasite development may seem arcane and unrelated to human health; however, genome-wide transcription studies can shed light on how parasites evade the host immune system. It is generally accepted that transcription of genes known to be involved in antigenic variation can switch among different members of a gene family and that this may contribute to immune evasion and pathogenicity 43 . Expression analysis and genome sequence has permitted the transcription of each of the 60 var genes, which encode versions of the variant surface antigen, PfEMP1, to be monitored, ultimately providing clues as to how antigenic variation in parasites may be regulated [44] [45] [46] . Genome-wide transcriptional and other studies have indicated that transcriptional switching may not be confined to var genes, encoding PfEMP1 proteins, and involve a large number of other different gene families such as those involved in parasite invasion 47, 48 . Notably, these expression data have also helped in the development of innovative vaccination strategies. For example, analysis of high-throughput P. falciparum proteomic data 27 revealed one exceptionally abundant sporozoite protein 49 , subsequently named CelTos in P. berghei 50 , which was more immunogenic than some of the historical antigens such as CSP. Antigens derived from this protein are found in an experimental vaccine that is entering clinical trials 51 . It has also been known that vaccination with radiation-attenuated parasites can lead to better protective immunity than can be achieved with a natural infection. Expression analysis has led to the identification of parasite genes that are specifically transcribed while the parasite resides in the mosquito salivary gland 52 . Disruption of these genes 53, 54 , or ones with similar patterns of transcription 55 , has led to genetically attenuated parasites which are unable to colonize successfully the vertebrate host but which nevertheless induce a protective immune response.
Genetic diversity in malaria parasites
The identity and geographic distribution of alleles that contribute to drug resistance forms the foundation for public policy on antimalarial drugs. Genome-dependent methods have the potential to change how genes involved in drug resistance are discovered. In the past genes involved in drug resistance were identified through mapping studies 56 , or through candidate gene approaches where alleles predicted to have a role in drug resistance in a different organism were correlated with resistance. Because microsatellite typing has previously revealed that haplotypes that surround the alleles involved in chloroquine resistance 57 and antifolate resistance 58 are statistically over-represented in parasite populations, there has been interest in collecting single-nucleotide polymorphism data in order to create a 'haplotype' map that can be used to identify new regions of the genome in disequilibrium in different drug-selected parasite populations [59] [60] [61] . Genome-dependent methods have also revealed new candidate genes that may be involved in drug resistance. Comparative genome hybridization with high-density oligonucleotide arrays show that different strains of P. falciparum contain numerous copy number variations (CNVs) that may be associated with drug resistance. For example, most strains carry diverse CNVs centred around the multidrug resistance transporter as well as around the first gene in the folate pathway, GTP cyclohydrolase 62 . This latter gene amplification event may be a signature of widespread antifolate drug use.
Studies of genetic variation [59] [60] [61] [62] [63] have provided clues as to why a universally effective single-subunit malaria vaccine may be difficult to develop. Clearly there are vastly different rates of variability in different parasite gene classes, with many genes involved in 'housekeeping' functions, such as ribosomal proteins, DNA replication enzymes, or components of the cytoskeleton, exhibiting very low levels of variability as one compares the genomes of different P. falciparum isolates from different continents, suggesting a recent population bottleneck or a selective sweep 64 . In contrast, many genes that are members of the multigene families, or which are membrane proteins, show very high levels of variability 65 , possibly indicating a basal evolution rate that is much higher than for housekeeping genes, occurring even during standard laboratory culture. These data also show high levels of allelic diversity in many of the genes that correspond to antigens used in vaccine trials, including CSP, the apical membrane antigen 1 and the merozoite surface protein 1. In some cases the high level of variability in these proteins may explain allelespecific immunity that is sometimes observed 66 . These diversity data suggest that it may be difficult to develop a single-subunit vaccine that can provide universal protection, but they also point to new vaccine candidates that show imprints of host immune selection.
From the genome to cell biology
One of the more exciting recent developments that has resulted from the genome sequencing efforts has been the observation that many of the proteins that eventually find their way out of the parasite and onto the surface of infected red blood cells carry a conserved protein export motif, called a VTS or PEXEL motif 67, 68 . After a cell is infected, malaria parasites form a parasitophorous vacuole in the host cell and soon afterwards a tubovesicular network to promote protein trafficking (Fig. 2) . Trafficking is likely to go in both directions, with both import of nutrients and export of proteins involved in immune evasion occurring. Remarkably, the PEXEL/VTS motif is also found in exported proteins from the plant pathogen, Phytophthora infestans, the organism responsible for the blight that caused the Irish potato famine 69 .
Here, the motif is attached to small proteins introduced into the plant cytoplasm where they interfere with the plant defence systems by preventing protease activation and subsequent apoptosis 70, 71 . Many of the 400 or so P. falciparum proteins that contain the PEXEL/VTS motif seem to be involved in creating 'knobby' structures on the surface of the infected red blood cell and are also associated with cytoadherence and antigenic variation; however, the motif is also found in proteins of parasites that do not cytoadhere, such as P. vivax 72 . In addition, whereas many are transcribed at the time that the tubovesicular network is established during development in the erythrocyte, a few seem to be transcribed in the pre-erythrocytic phase, at about the same time that proteins required for early liver stage development are transcribed 72 . One such protein is CSP, the target of the RTS,S vaccine, which bears two PEXEL/VTS motifs 73 . CSP has attracted attention over the years because it is probably the most abundant protein synthesized in the infectious sporozoite stage of the parasite's life cycle. The protein is immunogenic, functioning potentially as the immunodominant antigen in the irradiated sporozoite vaccine 74 . Although it has an essential role in the mosquito phases 75 of parasite development, its exact cellular role has been a matter of debate. Recently the PEXEL/VTS motif from CSP was attached to reporter proteins, where it directed the reporter protein into the cytoplasm of cells 73 , raising the possibility that CSP might have a role in host-pathogen interactions. Notably, transient overexpression of CSP in HeLa cells seems to have a substantial effect on host transcription, downregulating many genes involved in immune signalling and upregulating other genes involved in cell adhesion and possibly apoptosis 73 . It has been noted that parasites can grow for many days in the liver without triggering apoptosis or an inflammatory response, and once they have matured in the hepatocytes and are ready to be released the infected hepatocytes 'round up' and lose their ability to adhere 76 . Active immune modulation is know to occur in other parasitic infections, such as schistosomiasis, and is likely to be a signature of a successful pathogen. Indeed, a secreted protein kinase affecting gene expression has recently been identified as a major virulence factor in Toxoplasma gondii, a closely related apicomplexan parasite 77, 78 .
The genome and drug discovery
The availability of genome sequence has also coincided with a renaissance in malaria drug discovery, as malaria research has become more tractable and more funding has been directed towards drug development through the establishment of public-private partnerships. When the genome sequences first began to appear in the literature, researchers noted several pathways that appeared to be present in parasites but absent in higher eukaryotes 20 . These included the type II fatty acid biosynthesis pathway that is associated with the apicoplast, a unique organelle found in apicomplexan parasites. Although new, parasite-specific drug targets are still of substantial interest, recent drug discovery campaigns may be shifting from the single-enzyme screening approaches to cell-based methods where one can test for inhibition of all essential proteins simultaneously [79] [80] [81] . Cell-based methods have been less attractive in the past because of the difficulties associated with finding a compound's mechanism of action. The availability of genome-dependent methods (for example, tiling microarrays or deep full-genome sequencing that can pick up new mutations that have been introduced in the laboratory as a consequence of drug pressure), sensitive proteomic methods that can be used in affinity chromatography experiments, as well as new robots and high-content imaging systems may also make the daunting task of discovering what compounds are doing in the cell less challenging.
Despite the advances there is still much work ahead. For example, the RTS,S and irradiated sporozoite vaccines are both imperfect and many feel that other approaches should be examined in parallel, especially as RTS,S is only partially efficacious. There are also logistical hurdles associated with distributing either an attenuated or killed organism vaccine. Testing vaccines remains extremely expensive because there is no way to tell whether a vaccine is effective except through the use of human subjects. There are hurdles in the drug development front because it is likely that most of the compounds that have shown the ability to kill parasites in the laboratory setting will not be modifiable into something that could be feasibly and safely delivered to patients in Africa. In addition to problems with delivering drugs, educating local physicians and accessing at-risk populations, there are inadequate methods available for surveillance and to even determine whether the World Health Organization's roll back malaria campaigns (http://www.rbm.who.int/) are having an effect. Despite this, during this renaissance in malaria research optimism has reached a point where some are calling for new campaigns to 67, 68 . Some of these proteins, such as PfEMP1s, eventually reach the surface of the infected erythrocyte where they have a role in antigenic variation and immune evasion. Some may also be released in the bloodstream. b, In the liver stages of a malaria infection CSP and potentially other effector proteins may pass through the cytoplasm and eventually reach the nucleus (N). These proteins may interfere with the import of nuclear factor-kB 73 , a protein needed for activation of the human immune response, or they may have other roles controlling hepatocyte physiology. c, Small eukaryotic plant pathogens use a similar pathway with PEXEL/VTS-containing effector proteins released into the plant cytoplasm where they may interfere with plant innate immune defences 82 .
eliminate malaria completely. If basic research continues to be a priority and if support is sustained, new drugs and effective vaccines are likely to be developed, and this could make the goal of global malaria eradication achievable.
